SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Places Partial Clinical Hold on Bright Minds’ IND for DEE

SquawkNews Desk 2 updates Updated Nov 02, 2026, 12:32 PM UTC

Story updates

12:32:06 PM UTC
SquawkNews
BRIGHT MINDS BIOSCIENCES - PARTIAL CLINICAL HOLD APPLIES ONLY TO PLANNED PHASE 2 TRIAL OF BMB-101 IN
12:32:22 PM UTC
SquawkNews
BRIGHT MINDS BIOSCIENCES - AWAITING FDA PARTIAL CLINICAL HOLD LETTER EXPECTED WITHIN 30 DAYS

Related stories

FDA Places Bright Minds Biosciences Seizure Drug Application on Partial Hold Bright Minds Biosciences said the FDA placed its drug application and planned trial for a seizure treatment on partial clinical hold following a review. The stock fell 36% to $35 i M impact | REGULATION | Nov 02, 2026, 01:19 PM UTC NRx Pharmaceuticals Receives FDA Approval for Preservative-Free Ketamine NRx Pharmaceuticals said the FDA approved its preservative-free ketamine application ahead of the agency’s November 10 goal date. M impact | REGULATION | Nov 02, 2026, 01:13 PM UTC UniQure Says FDA Accepts Application for Huntington’s Gene Therapy UniQure said the FDA accepted an application for its potential Huntington’s disease gene therapy. L impact | REGULATION | Nov 02, 2026, 01:06 PM UTC Catheter Precision Announces FDA 510(k) Clearance for VIVO System The clearance enables use of the VIVO system in a broader patient population. L impact | REGULATION | Nov 02, 2026, 01:05 PM UTC Lupin Receives U.S. FDA Approval for Amifampridine Tablets M impact | REGULATION | Nov 02, 2026, 12:34 PM UTC Inovio Wins FDA Accelerated Approval for VOCERYQ Inovio received FDA accelerated approval for VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. M impact | REGULATION | Nov 02, 2026, 12:23 PM UTC